Radha Solai, PA
Medical · San Diego, CANPI 1245759695
Payments from drug & device makers
Across 208 payments — averaging $22.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$775
- AstraZeneca$631
- Johnson & Johnson$348
- Merck$314
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$279
- Lilly USA, LLC$271
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,727100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 50 | $775 |
| AstraZeneca | 23 | $631 |
| Johnson & Johnson | 15 | $348 |
| Merck | 14 | $314 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $279 |
| Lilly USA, LLC | 11 | $271 |
| Boehringer Ingelheim | 14 | $269 |
| Cvrx, Inc. | 4 | $255 |
| Boston Scientific | 8 | $162 |
| Alnylam Pharmaceuticals Inc. | 7 | $157 |
| Novo Nordisk | 3 | $153 |
| Amgen | 2 | $140 |
| E.r. Squibb & Sons, L.L.C. | 6 | $135 |
| Pfizer | 5 | $113 |
| Kiniksa Pharmaceuticals, Ltd. | 5 | $100 |
| Exact Sciences | 4 | $72 |
| Abbott | 4 | $72 |
| AbbVie | 3 | $66 |
| Tempus AI, Inc | 3 | $52 |
| Inspire Medical Systems, Inc. | 1 | $48 |
| Edwards Lifesciences | 1 | $34 |
| Bayer | 1 | $30 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Hologic Sales And Service, LLC | 1 | $25 |
| Gilead | 1 | $25 |
| Irhythm Technologies, Inc. | 1 | $23 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $22 |
| Phadia US Inc. | 1 | $21 |
| Philips North America LLC | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Coala Life Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,727 in reported general payments places this provider in the 85th percentile of 2,087 medical providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 61 | $94,139 |
| JardianceEmpagliflozin | 61 | $77,850 |
| EliquisApixaban | 64 | $66,542 |
| XareltoRivaroxaban | 35 | $50,743 |
| FarxigaDapagliflozin Propanediol | 27 | $34,517 |
| MounjaroTirzepatide | 21 | $32,521 |
| JanuviaSitagliptin Phosphate | 17 | $24,075 |
| OzempicSemaglutide | 13 | $19,581 |
| Repatha SureclickEvolocumab | 17 | $13,987 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $7,028 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $3,929 |
| Rosuvastatin Calcium | 128 | $2,689 |
| Atorvastatin Calcium | 158 | $1,649 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 42 | $1,598 |
| Nifedipine ErNifedipine | 42 | $1,217 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $775 | $94,13961 claims |
| Boehringer IngelheimJardiance | $269 | $77,85061 claims |
| PfizerEliquis | $113 | $66,54264 claims |
| Johnson & JohnsonXarelto | $348 | $50,74335 claims |
| AstraZenecaFarxiga | $631 | $34,51727 claims |
| Lilly USA, LLCMounjaro | $271 | $32,52121 claims |
| MerckJanuvia | $314 | $24,07517 claims |
| Novo NordiskOzempic | $153 | $19,58113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,087 medical providers in California.
Other medical in San Diego
- Cheryl KyinnSan Diego$103K
- Touraj YariSan Diego$27K
- Aaron WillcottSan Diego$23K
- Yuchao JinSan Diego$22K
- Carter CopelandSan Diego$17K
- Cameron ChanSan Diego$16K
- Nicola LowreyOrange$655K
- Justin LoveLoma Linda$553K
- David DoriguzziLancaster$514K
- Alison GracomIrvine$467K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.